Vitiligo Skin Biopsy Transcriptomic Profiles from Minimally Invasive 1mm Samples

105 skin biopsies from perilesional, lesional, and non-lesional skin of non-segmental vitiligo patients and healthy controls were analyzed using bulk RNA sequencing. The data, published by Danique Berrevoet in May 2026, reveals region-specific gene signatures related to immune activation and metabolic reprogramming. It includes results from differential gene expression, pathway analysis, and Connectivity Map-based therapeutic compound predictions.

Use Cases

• Identify differential gene expression patterns based on transcriptomic profiles from lesional, perilesional, and non-lesional skin.
• Analyze dysregulated biological pathways such as NOD-like receptor signaling and neutrophil extracellular trap formation mentioned in the description.
• Predict candidate therapeutic compounds using Connectivity Map-based perturbational profiling on the lesional transcriptional signature.
• Compare disease-associated transcriptomic changes between vitiligo patients and healthy control skin samples.

Strengths

• Dataset includes 105 skin biopsies, providing a basis for comparative analysis.
• Uses a minimally invasive 1mm biopsy technique, which the description suggests reduces scarring and healing time compared to conventional methods.
• Analysis includes multiple layers: differential gene expression, pathway analysis, and therapeutic compound prediction.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small in size (81.8 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Bulk RNA sequencing performed on skin biopsies from vitiligo patients and healthy controls.

Freshness

Last updated 2026-05-14 05:23:39; freshness should be verified.